Literature DB >> 128562

The Raji cell radioimmune assay for detecting immune complexes in human sera.

A N Theofilopoulos, C B Wilson, F J Dixon.   

Abstract

A sensitivie and simple procedure for the detection and quantitation of soluble complement (C)- fixing immune complexes in sera of patients with various disease states has been developed by utilizing C receptors on Raji cells. These cells lack membrane-bound immunoglobulin but have receptors for IgG Fc, C3b, C3d, and possibly with other C proteins. Uptake experiments showed that both aggregated human gamma globulin (AHG) and 7S IgG bound to receptors for IgG Fc; however, AHG reacted with C bound to cells only via receptors for C and this binding was much more efficient than via IgG Fc receptors. AHG was used as an in vitro model of human immune complexes and its uptake by Raji cells was quantitated by 125I-radiolabeled antihuman IgG. The limit of sensitivity of this test was 6 mug AHG/ml serum. The ability of Raji cells to detect AHG in serum depended on the amount of radioactive antibody used and the size of aggregates. The presence of an excess of C somewhat inhibited binding of AHG containing C to Raji cells. The efficient binding of AHG by receptors for C on Raji cells was used for the detection and quantitation of immune complexes in human sera. Raji cells were incubated with sera to be tested and then reacted with excess radiolabeled antihuman IgG; the amount of radioactivity bound to the washed cells was determined and referred to a standard curve of radioactive antibody uptake by cells previously incubated with increasing amounts of AHG in serum. Thereby immune complexes were detected and quantitated in serum hepatitis, systemic lupus erythematosus, vasculitis, subacute sclerosing panencephalitis, dengue hemorrhagic fever, and malignancies.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 128562      PMCID: PMC436637          DOI: 10.1172/JCI108257

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  67 in total

1.  BIOLOGICAL ACTIVITIES OF AGGREGATED GAMMA-GLOBULIN. VII. MINIMUM SIZE OF AGGREGATED GAMMA-GLOBULIN OR ITS PIECE 3 REQUIRED FOR THE INDUCTION OF SKIN REACTIVITY AND COMPLEMENT FIXATION.

Authors:  K ISHIZAKA; T ISHIZAKA; J BANOVITZ
Journal:  J Immunol       Date:  1965-06       Impact factor: 5.422

Review 2.  AUTOANTIBODIES AND DISEASE.

Authors:  H G KUNKEL; E M TAN
Journal:  Adv Immunol       Date:  1964       Impact factor: 3.543

Review 3.  Virus neutralization and virus-induced immune complex disease. Virus-antibody union resulting in immunoprotection or immunologic injury--two sides of the same coin.

Authors:  M B Oldstone
Journal:  Prog Med Virol       Date:  1975

4.  Circulating immune complexes in dermatitis herpetiformis.

Authors:  J F Mowbray; A V Hoffbrand; E J Holborow; P P Seah; L Fry
Journal:  Lancet       Date:  1973-02-24       Impact factor: 79.321

5.  Association between polyarteritis and Australia antigen.

Authors:  D J Gocke; K Hsu; C Morgan; S Bombardieri; M Lockshin; C L Christian
Journal:  Lancet       Date:  1970-12-05       Impact factor: 79.321

6.  Precipitin reactions of the C1q component of complement with aggregated gamma-globulin and immune complexes in gel diffusion.

Authors:  V Agnello; R J Winchester; H G Kunkel
Journal:  Immunology       Date:  1970-12       Impact factor: 7.397

7.  Enhanced uptake by guinea-pig macrophages of radio-iodinated human aggregated immunoglobulin G in the presence of sera from rheumatoid patients with cutaneous vasculitis.

Authors:  I I Onyewotu; P M Johnson; G D Johnson; E J Holborow
Journal:  Clin Exp Immunol       Date:  1975-02       Impact factor: 4.330

8.  Specific concentration of antilymphocyte antibodies in the serum cryoprecipitates of patients with systemic lupus erythematosus.

Authors:  J B Winfield; R J Winchester; P Wernet; H G Kunkel
Journal:  Clin Exp Immunol       Date:  1975-03       Impact factor: 4.330

9.  Interaction of aggregated -globulin with B lymphocytes.

Authors:  H B Dickler; H G Kunkel
Journal:  J Exp Med       Date:  1972-07-01       Impact factor: 14.307

10.  Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum.

Authors:  V A Bokisch; H J Müller-Eberhard; C G Cochrane
Journal:  J Exp Med       Date:  1969-05-01       Impact factor: 14.307

View more
  197 in total

1.  Rat spleen leucocyte (RSL) radioimmunoassay for the detection and quantification of soluble immune complexes.

Authors:  S F Al-Khateeb; T Barkas
Journal:  Clin Exp Immunol       Date:  1978-12       Impact factor: 4.330

2.  Serum factors influencing antibody-directed cell-mediated cytotoxicity (ADCC) and their effects on the detection of immune complexes by inhibition of ADCC.

Authors:  T Barkas; S F Al-Khateeb
Journal:  Immunology       Date:  1979-02       Impact factor: 7.397

Review 3.  Dengue: defining protective versus pathologic immunity.

Authors:  Alan L Rothman
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

4.  Evaluation of a Cordia-IC enzyme-linked immunosorbent assay kit for the detection of circulating immune complexes.

Authors:  Z Landoy; T E West; A O Vladutiu; J E Fitzpatrick
Journal:  J Clin Microbiol       Date:  1985-08       Impact factor: 5.948

5.  Does insulin administration contribute to immune complex formation in diabetes?

Authors:  L V Campbell; J A Charlesworth; G V Pasterfield; A Jenkins; B A Pussell
Journal:  Clin Exp Immunol       Date:  1984-11       Impact factor: 4.330

6.  Circulating immune complexes in normal pregnant women and in some conditions complicating pregnancy.

Authors:  R D'Amelio; P Bilotta; A Pachì; F Aiuti
Journal:  Clin Exp Immunol       Date:  1979-07       Impact factor: 4.330

7.  Circulating and deposited immune complexes in patients with glomerular disease: immunopathologic correlations.

Authors:  I Stachura; T L Whiteside; R H Kelly
Journal:  Am J Pathol       Date:  1981-04       Impact factor: 4.307

8.  Quantitation and characterization of soluble immune complexes precipitated from sera by polyethylene glycol (PEG).

Authors:  D Chia; E V Barnett; J Yamagata; D Knutson; C Restivo; D Furst
Journal:  Clin Exp Immunol       Date:  1979-09       Impact factor: 4.330

9.  Production of a suppressor factor by human adherent cells treated with Mycobacterium tuberculosis: absence in systemic lupus erythematosus.

Authors:  A A Wadee; A J Gear; A R Rabson
Journal:  Clin Exp Immunol       Date:  1981-10       Impact factor: 4.330

10.  Circulating immune complexes detected by 125I-Clq deviation test in sera of cancer patients.

Authors:  H Teshima; H Wanebo; C Pinsky; N K Day
Journal:  J Clin Invest       Date:  1977-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.